前列腺周围脂肪组织影响前列腺癌发展的机制

doi:10.3969/j.issn.1006-7795.2023.03.015

摘要/Abstract

摘要： 前列腺周围脂肪组织（periprostatic adipose tissue, PPAT）是包绕在前列腺周围的特殊脂肪组织，在代谢、炎症等方面具有独特的生物学特性。PPAT与前列腺癌的发生与发展密切相关。通过影像学测量的PPAT的厚度、体积等指标可为诊断和评估前列腺癌预后提供参考。PPAT与前列腺癌细胞之间存在活跃的相互作用，可通过多条分子通路影响前列腺癌的发展。对PPAT的研究将增进对前列腺癌发生机制的认识，有助于寻找新的治疗途径。

关键词: 脂肪组织, 前列腺癌, 影像学, 代谢, 炎症

Abstract: Periprostatic adipose tissue (PPAT), the special fat tissue surrounding the prostate gland, has unique characteristics in biological processes such as metabolism and inflammation. PPAT is closely related to the development and progression of prostate cancer. Imaging features of PPAT including PPAT thickness and volume may provide reference for the diagnosis and prognostic evaluation of prostate cancer. There are active interactions between PPAT and prostate cancer cells, which may influence prostate cancer development by several molecular pathways. The research on PPAT promotes our knowledge in the occurrence mechanism of prostate cancer, which is helpful to find new therapeutic approaches.

Key words: adipose tissue, prostate cancer, imaging, metabolism, inflammation

中图分类号:

R737.25

熊天宇, 牛亦农. 前列腺周围脂肪组织影响前列腺癌发展的机制[J]. 首都医科大学学报, 2023, 44(3): 457-462.

Xiong Tianyu, Niu Yinong. Mechanism of periprostatic adipose tissue affecting the development of prostate cancer[J]. Journal of Capital Medical University, 2023, 44(3): 457-462.

参考文献

［1］Zheng R S, Zhang S W, Zeng H M, et al. Cancer incidence and mortality in China, 2016［J］. J Nat Cancer Cent, 2022, 2(1): 1－9.
［2］Van Roermund J G H, Bol G H, Witjes J A, et al. Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness［J］. World J Urol, 2010, 28(6): 699－704.
［3］Tan W P, Lin C, Chen M R, et al. Periprostatic fat: a risk factor for prostate cancer?［J］. Urology, 2016, 98: 107－112.
［4］Dahran N, Szewczyk-Bieda M, Wei C, et al. Normalized periprostatic fat MRI measurements can predict prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localised disease［J］. Sci Rep, 2017, 7(1): 4630.
［5］lvarez-Artime A, García-Soler B, Sainz R M, et al. Emerging roles for browning of white adipose tissue in prostate cancer malignant behaviour［J］. Int J Mol Sci, 2021, 22(11): 5560.
［6］Finley D S, Calvert V S, Inokuchi J, et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness［J］. J Urol, 2009, 182(4): 1621－1627.
［7］Biondetti P R, Lee J K, Ling D, et al. Clinical stage B prostate carcinoma: staging with MR imaging［J］. Radiology, 1987, 162(2): 325－329.
［8］Yuh B, Wu H Q, Ruel N, et al. Analysis of regional lymph nodes in periprostatic fat following robot-assisted radical prostatectomy［J］. BJU Int, 2012, 109(4): 603－607.
［9］van Roermund J G H, Hinnen K A, Tolman C J, et al. Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients［J］. BJU Int, 2011, 107(11): 1775－1779.
［10］Bhindi B, Trottier G, Elharram M, et al. Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer［J］. BJU Int, 2012, 110(7): 980－986.
［11］Woo S, Cho J Y, Kim S Y, et al. Periprostatic fat thickness on MRI: correlation with Gleason score in prostate cancer［J］. AJR Am J Roentgenol, 2015, 204(1): W43-W47.
［12］Xiong T Y, Cao F, Zhu G Y, et al. MRI-measured adipose features as predictive factors for detection of prostate cancer in males undergoing systematic prostate biopsy: a retrospective study based on a Chinese population［J］. Adipocyte, 2022, 11(1): 653－664.
［13］Zhai L Y, Fan Y, Sun S S, et al. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer［J］. Scand J Urol, 2018, 52(5/6): 333－339.
［14］Iemura Y, Hori S, Tatsumi Y, et al. Periprostatic fat thickness quantified by preoperative magnetic resonance imaging is an independent risk factor forupstaging from cT1/2 to pT3 in robot-assisted radical prostatectomy［J］. Int J Urol, 2020, 27(12): 1144－1149.
［15］Salji M, Hendry J, Patel A, et al. Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer［J］. Eur Urol Focus, 2018, 4(6): 858－866.
［16］Huang H C, Chen S, Li W, et al. Periprostatic fat thickness on MRI is an independent predictor of time to castration-resistant prostate cancer in Chinese patients with newly diagnosed prostate cancer treated with androgen deprivation therapy［J］. Clin Genitourin Cancer, 2019, 17(5): e1036－e1047.
［17］Sasaki T, Sugino Y, Kato M, et al. Pre-treatment ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-nave men with advanced prostate cancer［J］. Int J Clin Oncol, 2020, 25(2): 370－376.
［18］Gregg J R, Surasi D S, Childs A, et al. The association of periprostatic fat and grade group progression in men with localized prostate cancer on active surveillance［J］. J Urol, 2021, 205(1): 122－128.
［19］Di Bella C M, Howard L E, Oyekunle T, et al. Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy［J］. Prostate, 2020, 80(14): 1244－1252.
［20］Lee J W, Jeon Y S, Kim K H, et al. Prognostic value of CT-attenuation and 18F-fluorodeoxyglucose uptake of periprostatic adipose tissue in patients with prostate cancer［J］. J Pers Med, 2020, 10(4): 185.
［21］Tafuri A, Panunzio A, Greco F, et al. MRI-derived apparent diffusion coefficient of peri-prostatic adipose tissue is a potential determinant of prostate cancer aggressiveness in preoperative setting: a preliminary report［J］. Int J Environ Res Public Health, 2022, 19(23): 15996.
［22］Allott E H, Howard L E, Song H J, et al. Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy［J］. Cancer Epidemiol Biomarkers Prev, 2014, 23(11): 2404－2412.
［23］Taussky D, Barkati M, Campeau S, et al. Changes in periprostatic adipose tissue induced by 5α-reductase inhibitors［J］. Andrology, 2017, 5(3): 511－515.
［24］Venkatasubramanian P N, Brendler C B, Plunkett B A, et al. Periprostatic adipose tissue from obese prostate cancer patients promotes tumor and endothelial cell proliferation: a functional and MR imaging pilot study［J］. Prostate, 2014, 74(3): 326－335.
［25］Iordanescu G, Brendler C, Crawford S E, et al. MRS measured fatty acid composition of periprostatic adipose tissue correlates with pathological measures of prostate cancer aggressiveness［J］. J Magn Reson Imaging, 2015, 42(3): 651－657.
［26］Miladinovic D, Cusick T, Mahon K L, et al. Assessment of periprostatic and subcutaneous adipose tissue lipolysis and adipocyte size from men with localized prostate cancer［J］. Cancers (Basel), 2020, 12(6): 1385.
［27］Roumiguié M, Estève D, Manceau C, et al. Periprostatic adipose tissue displays a chronic hypoxic state that limits its expandability［J］. Am J Pathol, 2022, 192(6): 926－942.
［28］Fontaine A, Bellanger D, Guibon R, et al. Lipophagy and prostate cancer: association with disease aggressiveness and proximity to periprostatic adipose tissue［J］. J Pathol, 2021, 255(2): 166－176.
［29］Altuna-Coy A, Ruiz-Plazas X, Sánchez-Martin S, et al. The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cells metabolic crosstalk［J］. BMC Med, 2022, 20(1): 255.
［30］Ribeiro R, Monteiro C, Catalán V, et al. Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue［J］. BMC Med, 2012, 10: 108.
［31］Mangiola S, Stuchbery R, Macintyre G, et al. Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer［J］. Endocr Relat Cancer, 2018, 25(5): 569－581.
［32］Cheng Y, Monteiro C, Matos A, et al. Epigenome-wide DNA methylation profiling of periprostatic adipose tissue in prostate cancer patients with excess adiposity-a pilot study［J］. Clin Epigenetics, 2018, 10: 54.
［33］Zhang Q,Sun L J, Qi J, et al. Influence of adipocytokines and periprostatic adiposity measurement parameters on prostate cancer aggressiveness［J］. Asian Pac J Cancer Prev, 2014, 15(4): 1879－1883.
［34］Zhang Q, Sun L J, Yang Z G, et al. Influence of adipocytokines in periprostatic adipose tissue on prostate cancer aggressiveness［J］. Cytokine, 2016, 85: 148－156.
［35］Dahran N, Szewczyk-Bieda M, Vinnicombe S, et al. Periprostatic fat adipokine expression is correlated with prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localized disease［J］. BJU Int, 2019, 123(6): 985－994.
［36］Gucalp A, Iyengar N M, Zhou X K, et al. Periprostatic adipose inflammation is associated with high-grade prostate cancer［J］. Prostate Cancer Prostatic Dis, 2017, 20(4): 418－423.
［37］Miyazawa M, Subbaramaiah K, Bhardwaj P, et al. Pioglitazone inhibits periprostatic white adipose tissue inflammation in obese mice［J］. Cancer Prev Res (Phila), 2018, 11(4): 215－226.
［38］Bhardwaj P, Ikeda T, Zhou X K, et al. Supplemental estrogen and caloric restriction reduce obesity-induced periprostatic white adipose inflammation in mice［J］. Carcinogenesis, 2019, 40(7): 914－923.
［39］Mangiola S, Stuchbery R, McCoy P, et al. Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat［J］. Endocr Connect, 2019, 8(5): 547－558.
［40］Ribeiro R, Monteiro C, Cunha V, et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro［J］. J Exp Clin Cancer Res, 2012, 31(1): 32.
［41］La Civita E, Liotti A, Cennamo M, et al. Peri-prostatic adipocyte-released TGFβ enhances prostate cancer cell motility by upregulation of connective tissue growth factor［J］. Biomedicines, 2021, 9(11): 1692.
［42］Figiel S, Bery F, Chantme A, et al. A novel calcium-mediated EMT pathway controlled by lipids: an opportunity for prostate cancer adjuvant therapy［J］. Cancers (Basel), 2019, 11(11): 1814.
［43］Laurent V, Toulet A, Attané C, et al. Periprostatic adipose tissue favors prostate cancer cell invasion in an obesity-dependent manner: role of oxidative stress［J］. Mol Cancer Res, 2019, 17(3): 821－835.
［44］Laurent V, Guérard A, Mazerolles C, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity［J］. Nat Commun, 2016, 7: 10230.
［45］Xu L J, Shen M J, Chen X D, et al. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells［J］. Prostate, 2018, 78(5): 353－364.
［46］Liotti A, La Civita E, Cennamo M, et al. Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF－1 upregulation of TUBB2B beta-tubulin isoform［J］. Prostate, 2021, 81(7): 407－417.
［47］Lin G, Yang R, Banie L, et al. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor［J］. Prostate, 2010, 70(10): 1066－1073.
［48］Feng S Z, Lou K C, Luo C, et al. Obesity-related cross-talk between prostate cancer and peripheral fat: potential role of exosomes［J］. Cancers (Basel), 2022, 14(20): 5077.
［49］Sacca P A, Mazza O N, Scorticati C, et al. Human periprostatic adipose tissue: secretome from patients with prostate cancer or benign prostate hyperplasia［J］. Cancer Genomics Proteomics, 2019, 16(1): 29－58.